Fig. 3From: Cost-effectiveness of abemaciclib plus endocrine therapy in high-risk HR+/HER2–early breast cancer in ChinaOne-way sensitivity analysis iDFS, invasive disease-free survival; ICER: incremental cost-effectiveness ratioBack to article page